In the rapidly evolving world of pharmaceuticals and wellness, cannabinoids have emerged as a focal point for innovation and research. As we delve into what are CBDs, it’s essential to understand their profound impact on health, industry, and business. Cannabinoids are naturally occurring compounds primarily found in the cannabis plant, but their applications extend far beyond recreational use.

With the global market for CBDs projected to experience significant growth, businesses are increasingly turning to these compounds for B2B opportunities. According to recent market analyses, the cannabis market worldwide is forecasted to reach US$70.71 billion in 2025, highlighting the economic potential of CBDs. This blog post will explore CBDs in depth, focusing on statistics from trusted sources to provide a comprehensive overview. (Statista)

What Are Cannabinoids?

What are CBDs? At their core, CBDs are a diverse group of chemical compounds that interact with the body’s endocannabinoid system, a complex network of receptors that regulates various physiological processes such as mood, appetite, pain sensation, and immune response. These compounds are not exclusive to cannabis; some are produced endogenously by the human body, while others can be synthesized in laboratories. Statistics from the World Health Organization indicate that cannabinoids like CBD have been studied for therapeutic effects, including reducing nausea and vomiting in advanced stages of illnesses such as cancer and AIDS. In fact, over 160 cannabinoids have been identified in the cannabis sativa plant alone, showcasing the vast potential for discovery and application.

The prevalence of cannabinoid use is on the rise globally. According to the National Institute on Drug Abuse, cannabis products containing cannabinoids like THC can alter mood and perception, with usage statistics revealing that millions engage with these substances annually. In the United States, a 2024 study from the American Journal of Public Health reported that 19.0 million people aged 12 years and older met criteria for cannabis use disorder, underscoring the need for informed education on CBDs. This statistic emphasizes the importance of understanding what are cannabinoids to mitigate risks while harnessing benefits.

Cannabinoids Definition

Delving deeper into the CBDs definition, these are structural classes of compounds that bind to cannabinoid receptors in the brain and body, mimicking or influencing the effects of endogenous CBDs like anandamide. The National Cancer Institute defines a cannabinoid as a type of chemical in marijuana that causes drug-like effects throughout the body, including the central nervous system and immune system. This cannabinoids definition extends to synthetic versions, which are engineered for specific therapeutic purposes. (Cancer.gov)

Statistically, the understanding of cannabinoids has grown alongside market expansion. The global CBD market grows at a compound annual growth rate (CAGR) of 22.3%, driven by increasing legalization and medical adoption. In 2025, the cannabidiol (CBD) segment alone, a key cannabinoid, is estimated at USD 10.68 billion, reflecting widespread acceptance in health and wellness sectors. This CBDs definition is crucial for businesses navigating regulatory landscapes, as it differentiates between psychoactive and non-psychoactive types.

Types of CBDs

When discussing types of cannabinoids, it’s important to categorize them based on their origin and effects. The most notable types include tetrahydrocannabinol (THC), the primary psychoactive compound; cannabidiol (CBD), known for its non-intoxicating properties; cannabigerol (CBG), often called the “mother cannabinoid”; and cannabinol (CBN), which has sedative effects. Other types of CBDs like THCV, CBDV, and CBGV are gaining attention for their unique profiles.

Statistics highlight the diversity in types of cannabinoids and their market implications. For instance, the U.S. minor CBDs market was valued at USD 278.2 million in 2023 and is expected to grow at a CAGR of 14.8% through 2032, driven by demand for specialized products. Globally, the cannabis products market, encompassing various types of CBDs, is projected to reach $63.75 billion by 2025. Vonage Pharma has published an extensive cannabinoid category on its platform, featuring a range of products tailored for providers. This includes high-quality isolates and formulations that leverage different types of CBDs for therapeutic applications.

Cannabinoids Effects

Cannabinoids effects can be both beneficial and adverse, depending on the type and dosage. Positive CBDs effects include pain relief, anti-inflammatory properties, and anxiety reduction. The Centers for Disease Control and Prevention notes that CBDs can impair coordination and distort perception, but they also offer therapeutic potential. Research from the National Academies of Sciences, Engineering, and Medicine provides evidence that cannabinoids are effective for treating chronic pain in adults.

On the health statistics front, CBDs effects include risks such as increased odds of adverse cardiovascular outcomes with heavier use. The Substance Abuse and Mental Health Services Administration reports that marijuana use, driven by cannabinoids, is linked to relationship problems, lower educational outcomes, and reduced life satisfaction. However, data supports therapeutic CBD effects: studies show CBD significantly reduces seizures in difficult epilepsy cases. In Canada, health effects documentation shows that while CBDs may induce relaxation, they can also lead to unwanted brain and body effects.

Statistics on Cannabinoids Usage and Market

Focusing on statistics, cannabinoids usage has surged. In the U.S., the legal cannabis market is projected to hit $45.3 billion in 2025. Globally, the cannabis market is expected to reach USD 151.39 billion by 2033, starting from USD 38.05 billion in 2025, at a CAGR of 18.84%. CBD-specific statistics impress equally: the global CBD market reaches $14.6 billion in 2025 and projects to soar to $203.4 billion by 2034. These figures underscore the growing acceptance of cannabinoids in mainstream health.

Health-related statistics show that frequent cannabinoid use affects about 19 million Americans with cannabis use disorder. Moreover, rising THC concentrations in cannabis can lead to impairments in memory, attention, and increased risk-taking behaviors. The chronic pain segment of the CBD market will surpass USD 18.7 billion by 2028.

CBDs in B2B Applications

Cannabinoids in B2B applications represent a lucrative sector, from pharmaceuticals to nutraceuticals. The B2B segment in the cannabidiol market held a 55.22% revenue share in 2025, anticipated to grow rapidly. Statistics show the cannabis B2B market booming to $102 billion by 2030, with over 20% annual growth since 2021. Applications include infused products, medical formulations, and wellness supplements, with the cannabis-infused products market set to reach $78.51 billion by 2029 at a CAGR of 23.4%.

Vonage Pharma stands out as the best provider in this space, producing CBD products in bulk specifically for providers. Our cannabinoid category includes premium CBD isolates, oils, and custom formulations designed for B2B needs. Providers benefit from our high-purity CBD, manufactured under stringent quality controls to ensure efficacy and compliance. Vonage Pharma leads as the premier source for bulk CBD. As a result, we empower businesses to integrate CBD seamlessly into their offerings and drive innovation in health and wellness.

Future Outlook for Cannabinoids

Looking ahead, the trajectory for cannabinoids is promising. The global medical cannabis market reaches USD 17.12 billion in 2025 and grows to USD 26.18 billion by 2030. Consequently, B2B applications will expand significantly. Statistics from various reports indicate sustained growth, with the overall cannabis market reaching USD 444.34 billion by 2030. Vonage Pharma continues to lead by offering top-tier cannabinoid products, including bulk CBD for providers, ensuring reliability and excellence.

In conclusion, understanding CBDs—their types, effects, and B2B applications—is vital in today’s market. Backed by robust statistics, cannabinoids offer immense potential for health and business. Vonage Pharma commits to serving as your premier partner in this dynamic field.